Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (93)

« Back to Publications

Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response

Peralta Alvarez MP. et al, (2026), Vaccines, 14, 509 - 509

Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.

Ritchie AJ. et al, (2026), The Lancet. Infectious diseases

Rabies glycoprotein engineering for improved stability and expression.

English S. et al, (2025), Vaccine, 62

Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.

Ritchie AJ. et al, (2025), Vaccine, 47

Adenoviral vaccines—Infectious disease

Bliss CM. et al, (2025), 573 - 642

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex

Williams BG. et al, (2024), Nature Communications, 15

A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions.

Segireddy RR. et al, (2024), Malaria journal, 23

Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.

Joe CCD. et al, (2024), Biotechnology and bioengineering, 121, 176 - 191

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration

Zhang C. et al, (2023), npj Vaccines, 8

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Measurement of Adenovirus-Based Vector Heterogeneity.

Hickey JM. et al, (2023), Journal of pharmaceutical sciences, 112, 974 - 984

Rapid-response manufacturing of adenovirus-vectored vaccines

Joe CCD. et al, (2023), Nature Biotechnology, 41, 314 - 316

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298

Load More

1
2
3
4
5
6
7